Embecta Q4 Results Trump Estimates, Discontinues Insulin Patch Pump Program, Issues FY25 Outlook

Embecta Corp. (EMBC), a global diabetes care company, on Tuesday, reported financial results for the fiscal fourth quarter ended September 30, 2024, with net income and revenue exceeding consensus estimates. The company also announced a restructuring plan, to streamline operations.

Net income for the fiscal fourth quarter of 2024 was $14.6 million, or $0.25 per share, compared to $6.0 million, or $0.10 per share, in the same period last year.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com